Innere Medizin III, Uniklinik Ulm, Albert-Einstein-Allee 23, 89081 Ulm, Germany.
Cancer Treat Rev. 2011;37 Suppl 1:S2-7. doi: 10.1016/j.ctrv.2011.05.004. Epub 2011 Jun 8.
Immune modulatory drugs have been successfully used to treat patients with multiple myeloma (MM), myelodysplastic syndromes displaying loss of 5q (del5q MDS) and chronic lymphocytic leukemia (CLL). Immune modulatory drugs are used in first-line therapy in combination with functionally complementary compounds, but have also shown efficacy in refractory disease. However, their exact mode of action remains unclear. Here we describe the clinical impact of these compounds on MM, del5q MDS and CLL, discuss their mode of action with respect to intracellular targets, focus on the phenotypic changes that immune modulatory compounds induce in the tumor microenvironment and how they modulate the immune response.
免疫调节药物已成功用于治疗多发性骨髓瘤（MM）、表现出 5q 缺失的骨髓增生异常综合征（del5q MDS）和慢性淋巴细胞白血病（CLL）患者。免疫调节剂与功能互补的化合物联合用于一线治疗，但在难治性疾病中也显示出疗效。然而，它们的确切作用机制仍不清楚。在这里，我们描述了这些化合物对 MM、del5q MDS 和 CLL 的临床影响，讨论了它们针对细胞内靶点的作用机制，重点介绍了免疫调节化合物在肿瘤微环境中诱导的表型变化以及它们如何调节免疫反应。
